HIV Type-1 p24 Antibody [HIV1-24/661]

ELISA: order BSA-free format for coating

Immunocytochemistry (Acetone or paraformaldehyde fixed): 0.5-1 ug/ml for 30 min

IF: 0.5-1 ug/ml



The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the HIV Type-1 p24 antibody to be titered up or down for optimal performance.

Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load.

PBS with 0.1 mg/ml BSA and 0.05% sodium azide

0.2 mg/mL

Unconjugated

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

Recombinant HIV-1 Gag p24 protein was used as the immunogen for this antibody.

155348

Liquid

Protein G affinity chromatography

Infectious Disease

Optimal dilutions for each application to be determined by the researcher